No results for ‘’
ERIS Lifesciences Ltd
₹1399
(3.57%)
Tue, 09 Jun 2026, 11:54 pm
Health Technology
Pharmaceuticals: Major
24.5KERIS Lifesciences Share Price Live Chart
1 Day
(3.57%)
No Result Found
Summary
Market Cap (in Cr)
19373.78
Net Profit (in Cr)
374.67
P/B
6.76
Sector P/E
33.76
P/E
54.84
EV/EBITDA
20.81
Debt/Equity (Industry)
0.26
Interest Cover (Industry)
10.81
ROCE (Industry)
16.40
RONW (Industry)
14.39
ROE
13.77
ROCE
13.29
Debt/Equity
0.97
EPS (TTM)
45.65
Dividend Yield
0.52
Book Value
281.64
Interest Cover
3.11
Analysis
all
- Dividends paid are thoroughly covered by earnings (7.5x coverage).
- Dividends after 3 years are expected to be thoroughly covered by earnings (11x coverage).
- Eris Lifesciences's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Eris Lifesciences's earnings are expected to exceed the low risk growth rate next year.
- Eris Lifesciences is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
- Eris Lifesciences only just started paying a dividend, it is too early to tell if payments are increasing.
- It is too early to tell whether Eris Lifesciences has stable dividend payments.
- Eris Lifesciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Eris Lifesciences's dividend is below the markets top 25% of dividend payers in India (3.08%).
- Cash flow for Eris Lifesciences is expected to increase but not above the 50% threshold in 2 years time.
Shareholding
| Shareholders | MAR 2026 | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 |
|---|---|---|---|---|---|
| Promoters | 53.92 | 54.85 | 54.85 | 54.84 | 54.85 |
| FII | 6.39 | 6.85 | 7.21 | 8.40 | 8.43 |
| DII | 20.35 | 20.32 | 19.36 | 18.17 | 18.07 |
| Public | 19.33 | 17.99 | 18.57 | 18.59 | 18.66 |
| Government | 0 | 0 | 0 | 0 | 0 |
Technical Analysis
Support and Resistance
| Type | R3 | R2 | R1 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 1833 | 1625 | 1512 | 1417 | 1304 | 1209 | 1001 |
| Fibonacci | 1625 | 1545.54 | 1496.46 | 1417 | 1337.54 | 1288.46 | 1209 |
| Camarilla | 1456.20 | 1437.13 | 1418.07 | 1417 | 1379.93 | 1360.87 | 1341.80 |
Pivots Level: Classic
R3
+416
1833
R2
+208
1625
R1
+95
1512
S1
-113
1304
S2
-208
1209
S3
-416
1001
Moving Average
Period
Value
10-EMA
1371.21
20-EMA
1369.97
30-EMA
1368.70
50-EMA
1370.63
100-EMA
1398.10
200-EMA
1439.65
Corporate Actions
| Announcement Date | Purpose | Action | Ex Date |
|---|---|---|---|
| 20 May 2026 | board-meetings | Accounts, Quarterly Results, Interim Dividend | |
| 20 May 2026 | dividend | ₹7.21 Dividend /Share | 29 May 2026 |
| 13 Feb 2026 | board-meetings | Quarterly Results | |
| 30 Jun 2025 | agm | ||
| 07 Feb 2025 | dividend | ₹7.35 Dividend /Share | 13 Feb 2025 |
| 13 Jan 2025 | dividend | Interim Dividend - Rs. - 7.35 | 13 Feb 2025 |
| 04 Sept 2024 | agm | ||
| 17 Aug 2024 | agm | Annual General Meeting | 18 Sept 2024 |
| 15 Aug 2023 | agm | Annual General Meeting | 18 Sept 2023 |
| 07 Aug 2023 | agm |
Peer Comparison
ERIS Lifesciences Ltd
Torrent Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Dr Reddys Laboratories Ltd
Cipla Ltd
Divis Laboratories Ltd
ERIS Lifesciences Ltd About
ERIS Lifesciences manufactures, markets, and sells generic drugs. The Company provides a wide range of products in chronic and acute therapy segments which includes capsules, tablets, and sachets. Eris Lifesciences also focuses on hypertension, anti-diabetes, metabolic disorders, lipid lowering, and therapeutic areas. Eris Lifesciences serves the pharmaceutical markets in India.
Industry
Pharmaceuticals - Indian - Formulations
Founded
2007
Headquarters
CEO
Amit Indubhushan Bakshi
Employees
Contact
Website
http://www.eris.co.in
complianceofficer@erislifesciences.com
Phone
91-79-30451000
Location
8th Floor Commerce House -IV, Prahladnagar 100 FT Road, Ahmedabad, Gujarat, 380015
ERIS Lifesciences Ltd Company History
| Year | History |
|---|---|
| 2016 |
|
| 2017 |
|
| 2022 |
|
| 2023 |
|
| 2024 |
|
Deals
| Client Name | Deal Type | Order Side | QTY | Avg Price | Date |
|---|---|---|---|---|---|
| MOTILAL OSWAL FINANCIAL SERVICES LIMITED | bulk | Buy | 2079000 | 1350.18 | 03 Oct 2024 |
| RAKESH SHAH | bulk | Sell | 2000000 | 1350 | 03 Oct 2024 |
| EMERALD INVESTMENTS LIMITED | bulk | Sell | 9886882 | 1201 | 22 Aug 2024 |
| EMERALD INVESTMENTS LIMITED | block | Sell | 9886882 | 1201 | 22 Aug 2024 |
| INFINITY PARTNERS | bulk | Buy | 9886882 | 1201 | 22 Aug 2024 |
| INFINITY PARTNERS | block | Buy | 9886882 | 1201 | 22 Aug 2024 |
| FRANKLIN TEMPLETON MUTUAL FUND | bulk | Buy | 1094201 | 1000.04 | 15 Jul 2024 |
| RAKESH SHAH | bulk | Sell | 2000000 | 1000.12 | 15 Jul 2024 |
| BHIKHALAL CHIMANLAL SHAH | bulk | Sell | 1280000 | 913.09 | 31 Jan 2024 |
| BHIKHALAL CHIMANLAL SHAH | bulk | Sell | 820000 | 912.5 | 31 Jan 2024 |